PI3KC2β: A promising therapeutic target in myotubular myopathy

被引：0
|
作者：
Goret, Marie [1 ]
Massana-Munoz, Xenia [1 ]
Nattarayan, Vasugi [1 ]
Reiss, David [1 ]
Laporte, Jocelyn [1 ]
机构：
[1] Univ Strasbourg, Inst Genet & Biol Mol & Cellulaire IGBMC, INSERM U1258, CNRS UMR7104, Illkirch Graffenstaden, France
来源：
M S-MEDECINE SCIENCES | 2023年 / 39卷
关键词：
D O I：
10.1051/medsci/2023134
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Myotubular myopathy is a rare disease of genetic origin characterized by significant muscle weakness leading to respiratory disorders and for which no treatment exists today. In this paper, we show that inhibition of the activity of the enzyme PI3KC2 beta prevents the development of this myopathy in a mouse model of the disease, thus identifying a therapeutic target to treat myotubular myopathy in humans.
引用
收藏
页码：32 / 36
页数：5
相关论文
共 50 条
  • [1] The PI3KC2β kinase as a therapeutic target for myotubular myopathy
    Goret, Marie
    Laporte, Jocelyn
    M S-MEDECINE SCIENCES, 2024, 40 (02): : 133 - 136
  • [2] Inactivating the lipid kinase activity of PI3KC2β is sufficient to rescue myotubular myopathy in mice
    Massana-Munoz, Xenia
    Goret, Marie
    Nattarayan, Vasugi
    Reiss, David
    Kretz, Christine
    Chicanne, Gaetan
    Payrastre, Bernard
    Vanhaesebroeck, Bart
    Laporte, Jocelyn
    JCI INSIGHT, 2023, 8 (09)
  • [3] Combined deficiency of PI3KC2α and PI3KC2β reveals a nonredundant role for PI3KC2α in regulating mouse platelet structure and thrombus stability
    Petitjean, Claire
    Setiabakti, Natasha M.
    Mountford, Jessica K.
    Arthur, Jane F.
    Ellis, Sarah
    Hamilton, Justin R.
    PLATELETS, 2016, 27 (05) : 402 - 409
  • [4] Identifying selective PI3KC2α inhibitors
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2022, 21 (11) : 798 - 798
  • [5] PI3KC2α inhibition is antithrombotic in blood from hypercholesterolemic mice
    Setiabakti, Natasha M.
    Tarlac, Volga
    Larsson, Pia
    Hamilton, Justin R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (01) : 249 - 254
  • [6] Probing the inhibitor selectivity site of class II PI3KC2β
    Sundaram, Krithika
    Jennings, Ian
    Arcaro, Alexandre
    Thompson, Philip
    CANCER RESEARCH, 2014, 74 (19)
  • [7] PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers
    He, Ying
    Li, Wei
    Zhang, Meiling
    Wang, Hui
    Lin, Peilu
    Yu, Ying
    Huang, Bin
    Hao, Meng
    He, Jianuo
    Kong, Weiyao
    Luo, Dan
    Xu, Tengteng
    Wang, Jiaqi
    Huang, Ying
    Zhao, Qinwen
    Liu, Ying
    Zhang, Jie
    Nian, Yong
    Zhang, Lei
    Zhu, Bo
    Yin, Chengqian
    JOURNAL OF EXPERIMENTAL MEDICINE, 2025, 222 (03):
  • [8] PBT-6, a Novel PI3KC2γ Inhibitor in Rheumatoid Arthritis
    Kim, Juyoung
    Jung, Kyung Hee
    Yoo, Jaeho
    Park, Jung Hee
    Yan, Hong Hua
    Fang, Zhenghuan
    Lim, Joo Han
    Kwon, Seong-Ryul
    Kim, Myung Ku
    Park, Hyun-Ju
    Hong, Soon-Sun
    BIOMOLECULES & THERAPEUTICS, 2020, 28 (02) : 172 - 183
  • [9] PI3KC2α, a new spindle associated protein involved in genomic instability and tumorigenesis
    De Santis, M. C.
    Martini, M.
    Federico, G.
    Ghigo, A.
    Campa, C. C.
    Chiarle, R.
    Sapino, A.
    Hirsch, E.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S75 - S75
  • [10] Phosphatidlyinositol-3-kinase C2 beta (PI3KC2β) is a potential new target to treat IgE mediated disease
    Srivastava, Shekhar
    Li, Zhai
    Skolnik, Edward Y.
    PLOS ONE, 2017, 12 (08):
12345